Pharma Mar (OTCMKTS:PHMMF) Short Interest Up 1,430.8% in July

Pharma Mar (OTCMKTS:PHMMF) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 199 shares, a growth of 1,430.8% from the July 15th total of 13 shares. Based on an average daily trading volume, of 15 shares, the short-interest ratio is presently 13.3 days. Currently, 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PHMMF shares. Zacks Research upgraded Pharma Mar to a “hold” rating in a report on Monday, June 15th. BTIG Research started coverage on Pharma Mar in a report on Thursday, April 23rd. They set a “buy” rating for the company. Finally, Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy”.

Pharma Mar Price Performance

Shares of OTCMKTS PHMMF remained flat at $87.58 during mid-day trading on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The company’s 50-day simple moving average is $87.24 and its two-hundred day simple moving average is $93.68. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.